BIOENVISION
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.
BIOENVISION
Industry:
Artificial Intelligence Biotechnology Marketing
Founded:
1996-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.bioenvision.com
Total Employee:
1+
Status:
Closed
Contact:
212-750-6700
Total Funding:
7.41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Mobile Non Scaleable Content Varnish OVH
Current Advisors List
Founder
Investors List
Aisling Capital
Aisling Capital investment in Venture Round - Bioenvision
Perseus
Perseus investment in Venture Round - Bioenvision
Official Site Inspections
http://www.bioenvision.com
- Host name: ip102.ip-54-38-216.eu
- IP address: 54.38.216.102
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
